Document Classification

Section Type: METHODS

Text: 244 patients with > 3 N + were randomized to receive either four 3-weekly courses of epirubicin (E : 100 mg/m (2), day 1) followed by four 4-weekly cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF : 600, 40, 600 mg/m (2), days 1, 8 : n = 122) or four 3-weekly courses of paclitaxel (T : 175 mg/m (2), day 1) followed by four 3-weekly cycles of epirubicin and vinorelbine (E : 75 mg/m (2), day 1 ; V : 25 mg/m (2), days 1, 8 : n = 122).